Comparative Pharmacology
Head-to-head clinical analysis: DYNACIRC CR versus TIAZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNACIRC CR versus TIAZAC.
DYNACIRC CR vs TIAZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
Isradipine extended-release (DynaCirc CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
Oral: 120-360 mg once daily; maximum 540 mg daily.
None Documented
None Documented
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker